Aim immunotech announces abstract accepted for presentation at 15th annual ihpba world congress

Ocala, fla., march 28, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced that study data evaluating the direct effects of ampligen® (rintatolimod) on human pancreatic ductal adenocarcinoma (pdac) cells was accepted for presentation at the 15th annual international hepato-pancreato-biliary association (ihpba) world congress being held march 30 – april 2, 2022 in new york, ny.
AIM Ratings Summary
AIM Quant Ranking